Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils.
IL‐5
airway remodelling
eosinophil‐associated diseases
epithelium
inflammatory cells
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
05
08
2024
received:
07
05
2024
accepted:
20
08
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
ppublish
Résumé
Interleukin (IL)-5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL-5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL-5 in eosinophil-associated diseases led to the development of anti-IL-5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL-5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL-5 biology relevant to disease pathogenesis beyond eosinophil-associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL-5 in type 2 inflammation.
Substances chimiques
Interleukin-5
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2662-2679Subventions
Organisme : GSK
Informations de copyright
© 2024 GSK and The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Pavord ID, Bel EH, Bourdin A, et al. From DREAM to REALITI‐A and beyond: mepolizumab for the treatment of eosinophil‐driven diseases. Allergy. 2022;77(3):778‐797.
Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in health and disease: a state‐of‐the‐art review. Mayo Clin Proc. 2021;96(10):2694‐2707.
Siddiqui S, Bachert C, Bjermer L, et al. Eosinophils and tissue remodeling: relevance to airway disease. J Allergy Clin Immunol. 2023;152(4):841‐857.
US PI1. GSK. NUCALA (mepolizumab) US prescribing information. Updated 2023. Accessed December 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf
US PI2. Teva Pharmaceutical Industries Ltd. CINQAIR (reslizumab) US prescribing information. Updated 2016. Accessed December 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf
US PI3. AstraZeneca Pharmaceuticals LP. FASENRA (benralizumab) US prescribing information. Updated 2017. Accessed December 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf
EMA PI1. GSK. NUCALA (mepolizumab) summary of product characteristics. Updated 2023. Accessed January 2024. https://www.ema.europa.eu/en/documents/product‐information/nucala‐epar‐product‐information_en.pdf
EMA PI2. Teva Pharmaceutical Industries Ltd. CINQAIR (reslizumab) summary of product characteristics. Updated 2016. Accessed January 2024. https://www.ema.europa.eu/en/documents/product‐information/cinqaero‐epar‐product‐information_en.pdf
EMA PI3. AstraZeneca Pharmaceuticals LP. FASENRA (benralizumab) summary of product characteristics. Updated 2017. Accessed January 2024. https://www.ema.europa.eu/en/documents/product‐information/fasenra‐epar‐product‐information_en.pdf
Caminati M, Maule M, Bello F, Emmi G. Biologics for eosinophilic granulomatosis with polyangiitis. Curr Opin Allergy Clin Immunol. 2023;23(1):36‐43.
Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Anti‐IL‐5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):Cd010834.
Kouverianos I, Angelopoulos A, Daoussis D. The role of anti‐eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review. Rheumatol Int. 2023;43(7):1245‐1252.
Kuang FL, Khoury P, Weller PF, Wechsler ME, Klion AD. Biologics and Hypereosinophilic syndromes: knowledge gaps and controversies. J Allergy Clin Immunol Pract. 2023;11(9):2666‐2671.
Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello‐Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta‐analysis. J Allergy Clin Immunol. 2022;149(4):1286‐1295.
Lommatzsch M, Nair P, Virchow JC. Normal blood eosinophil counts in humans. Respiration. 2024;103(4):214‐216.
Lyons PA, Peters JE, Alberici F, et al. Genome‐wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120.
Moore WC, Fitzpatrick AM, Li X, et al. Clinical heterogeneity in the severe asthma research program. Ann Am Thorac Soc. 2013;10(suppl):S118‐S124.
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy. 2022;77(3):812‐826.
Khoury P, Makiya M, Klion AD. Clinical and biological markers in hypereosinophilic syndromes. Front Med. 2017;4:240.
Siddiqui S, Wenzel SE, Bozik ME, et al. Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;152(5):1121‐1130.e1110.
Laidlaw TM, Prussin C, Panettieri RA, et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope. 2019;129(2):E61‐e66.
Gevaert P, Han JK, Smith SG, et al. The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022;12(11):1413‐1423.
Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743‐767.
Galdiero MR, Varricchi G, Seaf M, Marone G, Levi‐Schaffer F, Marone G. Bidirectional mast cell‐eosinophil interactions in inflammatory disorders and cancer. Front Med. 2017;4:103.
Barretto KT, Brockman‐Schneider RA, Kuipers I, et al. Human airway epithelial cells express a functional IL‐5 receptor. Allergy. 2020;75(8):2127‐2130.
Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):574‐584.
Kalinauskaite‐Zukauske V, Januskevicius A, Janulaityte I, Miliauskas S, Malakauskas K. Serum levels of epithelial‐derived cytokines as Interleukin‐25 and thymic stromal lymphopoietin after a single dose of mepolizumab in patients with severe non‐allergic eosinophilic asthma: a short report. Can Respir J. 2019;2019:8607657.
Likonska A, Nowak‐Jurek A, Gajewski A, et al. Mepolizumab therapy decreases epithelial‐derived cytokine concentrations in exhaled breath condensates from patients with severe eosinophilic asthma. Clin Exp Allergy. 2023;53(8):846‐849.
Rakkar K, Pang YL, Rajasekar P, et al. Mepolizumab induced changes in nasal methylome and transcriptome to predict response in asthma. Am J Respir Crit Care Med. 2024;209(10):1268‐1272.
Buchheit KM, Dwyer DF, Ordovas‐Montanes J, et al. IL‐5Ralpha marks nasal polyp IgG4‐ and IgE‐expressing cells in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2020;145(6):1574‐1584.
Sohail A, Hacker J, Ryan T, et al. Nasal polyp antibody‐secreting cells display proliferation signature in aspirin‐exacerbated respiratory disease. J Allergy Clin Immunol. 2024;153(2):527‐532.
Ochi H, De Jesus NH, Hsieh FH, Austen KF, Boyce JA. IL‐4 and ‐5 prime human mast cells for different profiles of IgE‐dependent cytokine production. Proc Natl Acad Sci USA. 2000;97(19):10509‐10513.
Dahl C, Hoffmann HJ, Saito H, Schiøtz PO. Human mast cells express receptors for IL‐3, IL‐5 and GM‐CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy. 2004;59(10):1087‐1096.
Otani IM, Anilkumar AA, Newbury RO, et al. Anti‐IL‐5 therapy reduces mast cell and IL‐9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2013;131(6):1576‐1582.
Bischoff SC, Brunner T, De Weck AL, Dahinden CA. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med. 1990;172(6):1577‐1582.
Yamada T, Sun Q, Zeibecoglou K, et al. IL‐3, IL‐5, granulocyte‐macrophage colony‐stimulating factor receptor alpha‐subunit, and common beta‐subunit expression by peripheral leukocytes and blood dendritic cells. J Allergy Clin Immunol. 1998;101(5):677‐682.
Büttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti‐interleukin‐5 treatment suppresses eosinophil but not T‐cell functions. Eur Respir J. 2003;21(5):799‐803.
Hirai K, Yamaguchi M, Misaki Y, et al. Enhancement of human basophil histamine release by interleukin 5. J Exp Med. 1990;172(5):1525‐1528.
Borish L, Teague WG, Patrie JT, et al. Further evidence of a type 2 inflammatory signature in chronic obstructive pulmonary disease or emphysema. Ann Allergy Asthma Immunol. 2023;130(5):617‐621 e611.
Gorski SA, Lawrence MG, Hinkelman A, et al. Expression of IL‐5 receptor alpha by murine and human lung neutrophils. PLoS ONE. 2019;14(8):e0221113.
Malik B, Bartlett NW, Upham JW, Nichol KS, Harrington J, Wark PAB. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics. Respirology. 2023;28(8):758‐766.
Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone‐dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529‐1532.e1528.
Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75‐86.e78.
Bergantini L, d'Alessandro M, Cameli P, et al. Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scand J Immunol. 2021;94(1):e13031.
Bergantini L, Pianigiani T, d'Alessandro M, et al. The effect of anti‐IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma. Biomed Pharmacother. 2023;166:115385.
Bajbouj K, AbuJabal R, Sahnoon L, Olivenstein R, Mahboub B, Hamid Q. IL‐5 receptor expression in lung fibroblasts: potential role in airway remodeling in asthma. Allergy. 2023;78(3):882‐885.
Domvri K, Siouprou I, Bakakos P, et al. Effect of mepolizumab on airways remodeling in patients with late‐onset severe eosinophilic asthma and fixed obstruction (preliminary data of the MESILICO study). Eur Respir J. 2023;62(suppl 67):OA3152.
Tsubokawa F, Koya T, Murai Y, et al. Effects of benralizumab on three‐dimensional computed tomography analysis in severe eosinophilic asthma. Int Arch Allergy Immunol. 2023;184(3):243‐251.
Yin Y, Mitson‐Salazar A, Wansley DL, Singh SP, Prussin C. Rapamycin preferentially inhibits human IL‐5(+) T(H)2‐cell proliferation via an mTORC1/S6 kinase‐1‐dependent pathway. J Allergy Clin Immunol. 2017;139(5):1701‐1704.e1710.
Janson C, Bjermer L, Lehtimäki L, et al. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges. Eur Clin Respir J. 2022;9(1):2040707.
Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol. 2020;145(6):1499‐1509.
Wilson SJ, Rigden HM, Ward JA, Laviolette M, Jarjour NN, Djukanović R. The relationship between eosinophilia and airway remodelling in mild asthma. Clin Exp Allergy. 2013;43(12):1342‐1350.
Al‐Shaikhly T, Murphy RC, Parker A, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. Eur Respir J. 2022;60(2):2101865.
Bankova LG, Barrett NA. Epithelial cell function and remodeling in nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):333‐341.
Ordovas‐Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018;560(7720):649‐654.
Wang M, Sun Y, Li C, Qu J, Zhou B. Eosinophils correlate with epithelial‐mesenchymal transition in chronic rhinosinusitis with nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2022;84(1):70‐80.
Corrado A, Ramonell RP, Woodruff MC, et al. Extrafollicular IgD+ B cells generate IgE antibody secreting cells in the nasal mucosa. Mucosal Immunol. 2021;14(5):1144‐1159.
Guillet C, Steinmann S, Lang C, Maul JT, Schmid‐Grendelmeier P. Eosinophil‐mast cell interaction: mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation. J Allergy Clin Immunol Pract. 2021;9(3):1393‐1395.e1391.
Wu C, Boey D, Bril O, et al. Single‐cell transcriptomics reveals the identity and regulators of human mast cell progenitors. Blood Adv. 2022;6(15):4439‐4449.
Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c‐kit(+), and expresses aminopeptidase N (CD13). Blood. 1999;94(7):2333‐2342.
Lommatzsch M, Marchewski H, Schwefel G, Stoll P, Virchow JC, Bratke K. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin Exp Allergy. 2020;50(11):1267‐1269.
Lawrence MG, Teague WG, Feng X, et al. Interleukin‐5 receptor alpha (CD125) expression on human blood and lung neutrophils. Ann Allergy Asthma Immunol. 2022;128(1):53‐60.e53.
Hakonarson H, Whelan R, Leiter J, et al. T lymphocyte‐mediated changes in airway smooth muscle responsiveness are attributed to induced autocrine release and actions of IL‐5 and IL‐1beta. J Allergy Clin Immunol. 2002;110(4):624‐633.
Wen FQ, Liu X, Manda W, et al. TH2 cytokine‐enhanced and TGF‐beta‐enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN‐gamma and corticosteroids. J Allergy Clin Immunol. 2003;111(6):1307‐1318.
Wu L, Oshima T, Li M, et al. Filaggrin and tight junction proteins are crucial for IL‐13‐mediated esophageal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G341‐G350.
De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773‐786.e771‐777.
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150‐155.
Straumann A, Conus S, Grzonka P, et al. Anti‐interleukin‐5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo‐controlled, double‐blind trial. Gut. 2010;59(1):21‐30.
Rothenberg ME, Dellon ES, Collins MH, et al. Eosinophil depletion with Benralizumab for eosinophilic esophagitis. N Engl J Med. 2024;390(24):2252‐2263.
Dellon E, Chehade M, Genta RM, et al. S446Results from KRYPTOS, a phase 2/3 study of Lirentelimab (AK002) in adults and adolescents with EoE. Am J Gastroenterol. 2022;117(10S):e316‐e317.
Calus L, Van Bruaene N, Bosteels C, et al. Twelve‐year follow‐up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy. 2019;9:30.
Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of long‐term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2020;41(1):102286.
Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L. Profile of anti‐IL‐5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy. 2015;8:105‐114.
Ogasawara H, Furuno M, Edamura K, Noguchi M. Peptides of major basic protein and eosinophil cationic protein activate human mast cells. Biochem Biophys Rep. 2020;21:100719.
Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 2014;134(3):671‐678.e674.
Sasano H, Harada N, Harada S, et al. Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real‐world response after 1‐year mepolizumab treatment in asthmatics. Allergol Int. 2024;73(1):94‐106.
Balzar S, Chu HW, Silkoff P, et al. Increased TGF‐beta in severe asthma with eosinophilia. J Allergy Clin Immunol. 2005;115(1):110‐117.
Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986;77(4):527‐537.
Holgate ST, Lackie PM, Howarth PH, et al. Invited lecture: activation of the epithelial mesenchymal trophic unit in the pathogenesis of asthma. Int Arch Allergy Immunol. 2001;124(1–3):253‐258.
Kasahara K, Shiba K, Ozawa T, Okuda K, Adachi M. Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma. Thorax. 2002;57(3):242‐246.
Holgate ST, Davies DE, Puddicombe S, et al. Mechanisms of airway epithelial damage: epithelial‐mesenchymal interactions in the pathogenesis of asthma. Eur Respir J Suppl. 2003;44:24s‐29s.
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973‐984.
Flood‐Page P, Menzies‐Gow A, Phipps S, et al. Anti‐IL‐5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029‐1036.
Chachi L, Diver S, Kaul H, et al. Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur Respir J. 2019;54(5):1900930.
Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add‐on therapy on health‐related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double‐blind, placebo‐controlled, parallel‐group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390‐400.
Graff S, Brusselle G, Hanon S, et al. Anti–Interleukin‐5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry. J Allergy Clin Immunol Pract. 2022;10(2):467‐477.
Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A. Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. 2024;79:1195‐1207.
Cavaliere C, Masieri S, Greco A, Lambiase A, Segatto M. Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2021;126(4):442‐443.
Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony‐stimulating factor and interleukin‐5. Am J Respir Cell Mol Biol. 1997;17(1):70‐77.
Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2‐mediated sensitization and inflammation in the lung. Nat Med. 2004;10(10):1095‐1103.
Desrosiers M, Diamant Z, Castelnuovo P, et al. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. Int Forum Allergy Rhinol. 2024;14(1):18‐31.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet (London, England). 2019;394(10209):1638‐1650.
Sohail A, Cho L, Hacker J, et al. Human nasal epithelial cells express IL‐5Rα but not the co‐receptor CSF2RB and do not signal to IL‐5. Allergy. 2024. doi:10.1111/all.16218
Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141‐1153.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double‐blind, placebo‐controlled trial. Lancet (London, England). 2012;380(9842):651‐659.
Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162.
Moermans C, Brion C, Bock G, et al. Sputum type 2 markers could predict remission in severe asthma treated with anti‐IL‐5. Chest. 2023;163(6):1368‐1379.
Robles‐Remacho A, Sanchez‐Martin RM, Diaz‐Mochon JJ. Spatial transcriptomics: emerging technologies in tissue gene expression profiling. Anal Chem. 2023;95(42):15450‐15460.
White JPE, Dubey S. Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev. 2023;22(1):103219.
Kolbeck R, Kozhich A, Koike M, et al. MEDI‐563, a humanized anti‐IL‐5 receptor alpha mAb with enhanced antibody‐dependent cell‐mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344‐1353 e1342.
Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo‐controlled trial. J Allergy Clin Immunol. 2022;149(4):1309‐1317.e1312.
Pham T‐H, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21‐29.
Vantaggiato L, Cameli P, Bergantini L, et al. Serum proteomic profile of asthmatic patients after six months of Benralizumab and mepolizumab treatment. Biomedicine. 2022;10(4):761.
Kuang FL, De Melo MS, Makiya M, et al. Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease. J Allergy Clin Immunol Pract. 2022;10(6):1598‐1605 e1592.
Kliewer KL, Murray‐Petzold C, Collins MH, et al. Benralizumab for eosinophilic gastritis: a single‐site, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(9):803‐815.
Dellon ES, Peterson KA, Murray JA, et al. Anti‐Siglec‐8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624‐1634.
Bolton SM, Kagalwalla AF, Arva NC, et al. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2020;115(2):224‐233.
Lopez AF, Vadas MA, Woodcock JM, et al. Interleukin‐5, interleukin‐3, and granulocyte‐macrophage colony‐stimulating factor cross‐compete for binding to cell surface receptors on human eosinophils. J Biol Chem. 1991;266(36):24741‐24747.
Wu J, Chandra RK, Li P, Hull BP, Turner JH. Olfactory and middle meatal cytokine levels correlate with olfactory function in chronic rhinosinusitis. Laryngoscope. 2018;128(9):E304‐e310.
Talbot S, Abdulnour RE, Burkett PR, et al. Silencing nociceptor neurons reduces allergic airway inflammation. Neuron. 2015;87(2):341‐354.
Drake MG, Scott GD, Blum ED, et al. Eosinophils increase airway sensory nerve density in mice and in human asthma. Sci Transl Med. 2018;10(457):eaar8477.
Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68(7):829‐835.
Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving Benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381‐4392.e4384.